Literature DB >> 18501654

Clinical significance of sequestration in adults with severe malaria.

A M Dondorp1.   

Abstract

Reduced microcirculatory flow is a fundamental feature in the pathophysiology of severe Plasmodium falciparum malaria and sequestration of red blood cells containing mature parasites is considered a central cause of this. Direct microscopic observation of the microcirculation in the living patient with severe malaria has enabled us to quantify this phenomenon and link it to severity of disease, supporting the findings of pathology studies. Moreover, the sequestered parasite biomass, calculated from parasite derived plasma PfHRP2 concentrations, strongly correlates with disease severity. Artesunate prevents sequestration by killing ring form parasites, aborting their maturation, which can explain the mortality benefit of this drug compared to quinine in the treatment of adult severe malaria. Levamisole is currently tried as adjunctive treatment in severe malaria targeting sequestration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501654     DOI: 10.1016/j.tracli.2008.04.013

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  13 in total

Review 1.  Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.

Authors:  Chandy C John; Elizabeth Kutamba; Keith Mugarura; Robert O Opoka
Journal:  Expert Rev Anti Infect Ther       Date:  2010-09       Impact factor: 5.091

Review 2.  Malaria link of hypertension: a hidden syndicate of angiotensin II, bradykinin and sphingosine 1-phosphate.

Authors:  Gunanidhi Dhangadamajhi; Shailja Singh
Journal:  Hum Cell       Date:  2021-03-08       Impact factor: 4.174

3.  High-throughput screening platform identifies small molecules that prevent sequestration of Plasmodium falciparum-infected erythrocytes.

Authors:  Justin Gullingsrud; Neta Milman; Tracy Saveria; Olga Chesnokov; Kathryn Williamson; Anand Srivastava; Benoit Gamain; Patrick E Duffy; Andrew V Oleinikov
Journal:  J Infect Dis       Date:  2014-10-29       Impact factor: 5.226

4.  Fatal Plasmodium falciparum, Clostridium perfringens, and Candida spp. Coinfections in a Traveler to Haiti.

Authors:  Gillian L Genrich; Julu Bhatnagar; Christopher D Paddock; Sherif R Zaki
Journal:  J Trop Med       Date:  2009-05-05

Review 5.  The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria.

Authors:  Patrice N Mimche; Donatella Taramelli; Livia Vivas
Journal:  Malar J       Date:  2011-03-15       Impact factor: 2.979

6.  A plasma survey using 38 PfEMP1 domains reveals frequent recognition of the Plasmodium falciparum antigen VAR2CSA among young Tanzanian children.

Authors:  Andrew V Oleinikov; Valentina V Voronkova; Isaac Tyler Frye; Emily Amos; Robert Morrison; Michal Fried; Patrick E Duffy
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

7.  Plasmodium falciparum infected erythrocytes can bind to host receptors integrins αVβ3 and αVβ6 through DBLδ1_D4 domain of PFL2665c PfEMP1 protein.

Authors:  Olga Chesnokov; Jordan Merritt; Sergey O Tcherniuk; Neta Milman; Andrew V Oleinikov
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

Review 8.  Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications.

Authors:  J Alexandra Rowe; Antoine Claessens; Ruth A Corrigan; Mònica Arman
Journal:  Expert Rev Mol Med       Date:  2009-05-26       Impact factor: 5.600

9.  Structure-function-immunogenicity studies of PfEMP1 domain DBL2βPF11_0521, a malaria parasite ligand for ICAM-1.

Authors:  Justin Gullingsrud; Tracy Saveria; Emily Amos; Patrick E Duffy; Andrew V Oleinikov
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

Review 10.  Expanding the antimalarial toolkit: Targeting host-parasite interactions.

Authors:  Jean Langhorne; Patrick E Duffy
Journal:  J Exp Med       Date:  2016-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.